Albumin Sales

Albumin Sales Market Outlook

The global albumin sales market is projected to reach approximately USD 9.2 billion by 2035, expanding at a compound annual growth rate (CAGR) of about 8.5% during the forecast period from 2025 to 2035. This robust growth is driven by the increasing prevalence of chronic diseases, the expanding applications of albumin in pharmaceuticals and therapeutics, as well as advancements in medical technology that enhance the efficacy of albumin-based treatments. Additionally, the rise in demand for safe and effective blood plasma substitutes and the growing biotechnology sector further fuel market expansion. The increasing focus on research and development to innovate new formulations and applications for albumin is expected to open up further opportunities in the coming years.

Growth Factor of the Market

Several key growth factors are propelling the albumin sales market forward, including the growing incidence of liver diseases, burns, and trauma, which necessitate the use of albumin in therapeutic treatments. Furthermore, the surge in demand for albumin in drug formulation and delivery, particularly in the biopharmaceutical sector, is fostering market growth. The increasing number of surgical procedures globally also contributes to the higher consumption of albumin for maintaining oncotic pressure in patients. Additionally, innovations in recombinant albumin production technology are enhancing the availability and reducing the cost of these essential products, thus making them more accessible in healthcare settings. Lastly, the rising investments in research initiatives aimed at exploring novel applications of albumin are creating a conducive environment for market expansion.

Key Highlights of the Market

• The global albumin market is expected to reach USD 9.2 billion by 2035.
• North America is anticipated to be the largest market contributor, accounting for over 40% of the total market share.
• The human serum albumin segment is projected to dominate the product type category due to its widespread application in therapeutics.
• There is a notable increase in the use of albumin-based drug formulations in the biopharmaceutical industry.
• Research-grade albumin is gaining traction due to rising investments in biomedical research and clinical trials.

By Product Type

Human Serum Albumin:

Human Serum Albumin (HSA) is one of the most widely used forms of albumin in medical applications, primarily utilized for therapeutic purposes. It plays a crucial role in the treatment of conditions such as hypovolemia, burns, and liver cirrhosis. HSA is favored for its ability to maintain oncotic pressure and its extensive usage in surgical and trauma settings. The growing number of clinical trials exploring the efficacy of HSA in various therapeutic areas has further propelled its demand. Moreover, the rising prevalence of liver diseases and the increasing number of surgeries contribute significantly to the growth of the Human Serum Albumin segment within the broader albumin market.

Bovine Serum Albumin:

Bovine Serum Albumin (BSA) is primarily used in laboratory research and diagnostics due to its stability and ability to bind various molecules. BSA is most commonly utilized in cell culture processes, enzyme reactions, and immunoassays. Its properties make it an essential component in the formulation of biological products, as it can stabilize other proteins and compounds. The demand for BSA is closely linked to the growth of the biotechnology and pharmaceutical industries, as innovations in laboratory techniques and assays continue to expand. Furthermore, the cost-effectiveness of BSA compared to human-derived albumin sources makes it a preferred choice for many researchers and laboratories globally.

Recombinant Albumin:

Recombinant Albumin is gaining traction in the market due to its advantages over traditionally sourced albumin. The production of recombinant albumin through genetic engineering offers a more controlled and consistent product, free from the risks associated with animal-derived products. Its applications are expanding within the biopharmaceutical industry, particularly for drug formulation and delivery systems. The increasing demand for biosimilars and biologics is expected to drive the adoption of recombinant albumin in therapeutic applications. As regulatory bodies continue to support the development of recombinant products, this segment's market share is likely to grow significantly in the coming years.

Pharmaceutical Grade Albumin:

Pharmaceutical Grade Albumin is specifically developed for use in clinical applications, ensuring that it meets stringent quality standards. It is utilized in various therapeutic applications, including parenteral nutrition and volume expansion in critical care settings. The rising incidence of diseases that require rapid volume replacement is driving the demand for pharmaceutical-grade albumin. Furthermore, as healthcare providers seek to adhere to higher standards of care, the preference for high-quality pharmaceutical-grade products is likely to continue increasing. Innovations in production methods that enhance the purity and safety of pharmaceutical-grade albumin are also expected to support market growth.

Research Grade Albumin:

Research Grade Albumin is primarily used in laboratory settings for various applications such as cell culture, diagnostics, and assays. It is designed for experimental purposes, where consistency and quality are paramount. As research activities increase globally, particularly in drug discovery and development, the demand for high-quality research-grade albumin is on the rise. The growth of the life sciences sector, driven by advancements in genomics, proteomics, and cell biology, contributes significantly to the expansion of this segment in the albumin market. Additionally, the increasing number of academic and private research institutions investing in biomedical research is propelling the growth of the research-grade albumin segment.

By Application

Therapeutics:

The therapeutics segment represents one of the largest applications of albumin, where it is utilized to treat a variety of medical conditions including liver failure, burns, and shock. Albumin's ability to maintain oncotic pressure and its role in fluid management make it indispensable in critical care scenarios. The increasing prevalence of chronic diseases, alongside a growing elderly population requiring medical intervention, is significantly driving the demand for albumin-based therapeutics. Moreover, the ongoing advancements in medical protocols and the rising number of surgical procedures further augment the need for albumin in therapeutic applications, signaling a robust growth trajectory for this segment.

Drug Formulation and Drug Delivery:

In recent years, the use of albumin in drug formulation and delivery systems has gained immense popularity, particularly within the biopharmaceutical industry. Albumin's unique properties facilitate the solubilization and stabilization of drugs, enhancing their bioavailability and efficacy. Moreover, its biocompatibility makes it an attractive choice for delivering therapeutic agents, particularly in targeted therapies. As pharmaceutical companies increasingly explore innovative formulations that leverage albumin's characteristics, this segment is witnessing accelerated growth. The demand for more effective and personalized drug delivery systems is anticipated to further fuel the application of albumin in drug formulation and delivery.

Vaccines:

Albumin is also used in the formulation of vaccines, acting as a stabilizer and carrier for antigens. The rise in vaccination campaigns, particularly in developing regions, along with the ongoing research to develop new vaccines, has led to an increased demand for albumin in this application. Its role in maintaining the stability and efficacy of vaccines under various storage conditions is critical. The global push for immunization against infectious diseases and the advancements in vaccine technology are expected to enhance the necessity for albumin formulations in the vaccine sector. Furthermore, as new vaccine development accelerates, this application segment is poised for significant growth.

Cell Culture:

Cell culture applications represent a vital area where albumin is extensively utilized. Albumin serves as a serum substitute, providing essential nutrients and growth factors required for cell proliferation and differentiation. The increasing investment in cell-based therapies and regenerative medicine is driving the demand for albumin in cell culture applications. As biopharmaceuticals continue to evolve, the need for high-quality albumin to support the growth of various cell lines is expected to rise. Furthermore, the growth of technologies in stem cell research and tissue engineering is likely to further enhance the relevance of albumin in cell culture settings.

Diagnostics:

In the diagnostics sector, albumin is used in various assays and diagnostic tests, primarily due to its ability to bind and stabilize proteins. The rising prevalence of diseases necessitating prompt diagnostic methods is driving the demand for albumin in this application. Its role in the formulation of reagents and as a control standard in immunoassays is critical for accurate test results. As the global healthcare landscape shifts towards personalized medicine, the need for reliable and efficient diagnostic tools is expected to grow, thus increasing the demand for albumin in the diagnostics space. This trend highlights the integral role of albumin in modern diagnostic practices.

By Distribution Channel

Hospitals and Clinics:

The hospitals and clinics segment represents the largest distribution channel for albumin, primarily due to the high volume of therapeutic applications in these settings. Hospitals often utilize albumin for various conditions requiring immediate intervention, such as trauma and surgeries. The growing number of hospitals equipped to handle critical care situations and the increasing incidences of chronic diseases contribute significantly to this channel's growth. Additionally, the presence of specialized departments, such as intensive care units, further drives the demand for albumin products in hospitals and clinics, ensuring optimal patient outcomes.

Online Pharmacies:

Online pharmacies have emerged as an important distribution channel for albumin, especially in the wake of the COVID-19 pandemic, which accelerated the adoption of e-commerce in the healthcare sector. The convenience of online purchasing, coupled with the ability to access a broader range of products, is driving the demand for albumin from online platforms. This channel offers patients and healthcare providers an accessible means to procure albumin, especially in regions with limited physical pharmacy options. The increasing trust in online pharmacies due to improved regulations and quality control measures further enhances their growth potential in the albumin market.

Retail Pharmacies:

Retail pharmacies continue to play a vital role in the distribution of albumin, catering to a wide customer base that includes both healthcare professionals and patients. The accessibility and availability of albumin products at retail outlets make it a convenient choice for many consumers. Furthermore, the increasing prevalence of chronic conditions that require regular albumin administration is fostering growth in retail pharmacy sales. Retail pharmacies often stock a variety of albumin formulations, making them a critical distribution channel for ensuring that patients have access to necessary therapeutics.

Drug Stores:

Drug stores serve as a significant distribution channel for albumin, offering an array of pharmaceutical products, including various types of albumin. This channel is particularly advantageous for consumers seeking over-the-counter solutions or those who require albumin for specific therapeutic needs. The growth of drug stores, particularly in urban areas, enhances accessibility for patients in need of albumin products. Additionally, promotional activities and educational campaigns conducted by drug stores to raise awareness of the therapeutic benefits of albumin contribute to the segment's expansion.

Others:

This category includes various niche distribution channels, such as specialty pharmacies and healthcare providers specializing in chronic disease management. These channels often cater to specific patient needs and provide tailored products, including albumin, for managing complex health conditions. The increasing recognition of the importance of personalized healthcare solutions is expected to drive the growth of this segment. Moreover, the integration of technology in health management, such as telehealth solutions, is likely to provide additional avenues for albumin distribution, particularly in remote areas.

By Ingredient Type

Fatty Acid-Free Albumin:

Fatty Acid-Free Albumin is primarily used in cell culture and biological applications, where the presence of fatty acids might interfere with experimental outcomes. This type of albumin is essential for researchers and laboratories aiming for specific results in their studies. The growing applications in biotechnology and pharmaceutical research are driving the demand for Fatty Acid-Free Albumin. Furthermore, the shift towards more controlled and defined laboratory conditions in research is likely to enhance the market for this ingredient type.

Low Fatty Acid Albumin:

Low Fatty Acid Albumin is designed to reduce the variability associated with fatty acids in experimental setups. This product type is particularly useful in applications where the manipulation of fatty acid concentrations is required, such as in metabolic studies and drug screening assays. The increase in academic and industrial research focusing on lipid metabolism and related diseases is expected to boost the demand for Low Fatty Acid Albumin. Its applications in both basic research and clinical studies underscore its significance in the broader albumin market.

Heat Shock Albumin:

Heat Shock Albumin is employed in various therapeutic and research applications due to its unique properties that enhance protein stability. This type of albumin is particularly essential in scenarios where temperature fluctuations can affect biological samples or formulations. The ongoing research into heat shock proteins and their roles in cellular processes is likely to drive demand for Heat Shock Albumin. Furthermore, its applications in drug formulation, particularly in stabilizing biologics, highlight its importance in the pharmaceutical industry.

Fatty Acid-Enriched Albumin:

Fatty Acid-Enriched Albumin is utilized in specialized therapeutic applications where the presence of fatty acids is beneficial for patient outcomes. This type of albumin is often used in parenteral nutrition formulations and can provide essential fatty acids to patients who are unable to consume them through diet. The increasing prevalence of malnutrition and related health issues in hospitalized patients is driving demand for Fatty Acid-Enriched Albumin. Its role in enhancing nutrient delivery and supporting metabolic functions underscores its significance in clinical nutrition practices.

Others:

This category encompasses various specialized albumin formulations tailored for specific applications. Such formulations may include modified albumins designed for unique therapeutic effects or enhanced stability. The increasing focus on personalized medicine and the ongoing research to develop innovative albumin products are expected to drive the growth of this segment. Moreover, as healthcare providers seek to optimize treatment regimens for patients, the demand for diversified albumin formulations is likely to rise.

By Region

The North America region dominates the global albumin sales market, accounting for over 40% of the total market share. The presence of advanced healthcare infrastructure, high healthcare expenditure, and well-established pharmaceutical and biotechnology sectors contribute significantly to this region's strong market position. The increasing prevalence of diseases requiring albumin for treatment, combined with ongoing research initiatives, is expected to drive robust growth in North America. Moreover, the regulatory environment in this region supports innovation and the approval of new albumin products, further enhancing market potential.

In Europe, the albumin market is expected to experience steady growth, driven by the rising incidence of chronic diseases and the increasing utilization of albumin in various therapeutic applications. The region's focus on research and development, particularly in the biopharmaceutical sector, is expected to contribute to the growth of the albumin market. Asia-Pacific is anticipated to witness the highest CAGR of approximately 9% during the forecast period, as emerging economies continue to enhance their healthcare infrastructure and increase investments in biopharmaceutical research. The growing population and rising awareness about healthcare are significant factors contributing to the expansion of the albumin market in this region.

Opportunities

The albumin sales market presents numerous opportunities for growth, particularly in the development of new pharmaceutical formulations and applications. With the increasing focus on personalized medicine, there is a growing demand for tailored albumin products that can meet specific therapeutic needs. Companies that invest in research and development to innovate and create specialized albumin formulations have the potential to capture significant market share. Additionally, as the global population ages, the demand for therapeutics to manage chronic conditions will increase, providing an opportunity for albumin to play a key role in treatment regimens.

Furthermore, the rising trend of biotechnology and biopharmaceutical research is likely to create substantial opportunities for albumin in laboratory settings. As researchers seek to optimize experimental conditions and enhance the stability of biological products, the demand for high-quality albumin is expected to grow. Collaborations between pharmaceutical companies and research institutions to explore novel applications of albumin could pave the way for innovative products and solutions in the healthcare market. The expanding market for biosimilars also presents opportunities for albumin as a stabilizing agent in drug formulations, supporting the overall growth of the albumin sales market.

Threats

Despite the positive growth trajectory of the albumin sales market, there are several threats that could impede progress. One major threat is the increasing concerns regarding the safety and sourcing of animal-derived products, which may lead to regulatory scrutiny and impact market acceptance. As healthcare providers and consumers become more conscious of product origins and ethical considerations, there may be a shift towards recombinant and synthetic alternatives, posing a challenge for traditional albumin products. Moreover, the rise in competition from alternative therapies and products could further pressure the albumin market, requiring companies to innovate continually to maintain their market positions.

Additionally, the volatility in raw material prices, particularly for human and bovine serum albumin, could have an adverse effect on manufacturing costs and profit margins. Fluctuations in supply chain dynamics, influenced by geopolitical factors or health crises like pandemics, could further disrupt the availability of albumin products in the market. Such uncertainties can create challenges for companies in planning and executing their business strategies effectively. Consequently, the need for robust risk management strategies is critical to navigate these threats and ensure sustainable growth in the albumin sales market.

Competitor Outlook

• CSL Limited
• Grifols S.A.
• Octapharma AG
• Shire Plc (Takeda Pharmaceutical Company)
• Baxter International Inc.
• Albumedix A/S
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Recombumin (biotech company)
• Proliant Biologicals
• Biotest AG
• HUMANZYMES, Inc.
• HemaCare Corporation
• Stemcell Technologies Inc.
• Zeus Scientific Inc.

The competitive landscape of the albumin sales market is characterized by the presence of several key players who dominate the industry through their innovative product offerings and strategic partnerships. Companies such as CSL Limited and Grifols S.A. lead the market due to their extensive portfolios of albumin products and established global distribution networks. These companies invest significantly in research and development to enhance their product lines and improve the efficacy and safety of their albumin formulations. The focus on quality assurance and compliance with regulatory standards is paramount, as these firms strive to maintain their competitive edge in a highly regulated market.

Another notable player, Baxter International Inc., has a strong reputation for its diverse range of albumin products that cater to various therapeutic applications, including critical care and surgical procedures. The company emphasizes innovation, with ongoing efforts to develop new albumin formulations that address unmet medical needs. Additionally, companies like Octapharma AG and Shire Plc (now part of Takeda Pharmaceutical Company) are also significant contributors to the albumin market, leveraging their strengths in biotechnology and plasma-derived products to expand their reach in the global market.

Emerging companies, such as Albumedix A/S and Recombumin, are gaining traction by focusing on recombinant albumin production, thereby providing high-quality, animal-free alternatives to traditional albumin sources. This trend is reshaping the competitive landscape, as more players recognize the potential of recombinant products to meet the growing demand for safe and effective albumin therapies. Moreover, collaborations between established and emerging players, as well as partnerships with research institutions, are expected to play a critical role in driving innovation and market growth in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Biotest AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Limited
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Grifols S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Albumedix A/S
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Octapharma AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 HUMANZYMES, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 HemaCare Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Proliant Biologicals
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Zeus Scientific Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Baxter International Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Stemcell Technologies Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Recombumin (biotech company)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire Plc (Takeda Pharmaceutical Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Albumin Sales Market, By Application
    • 6.1.1 Therapeutics
    • 6.1.2 Drug Formulation and Drug Delivery
    • 6.1.3 Vaccines
    • 6.1.4 Cell Culture
    • 6.1.5 Diagnostics
  • 6.2 Albumin Sales Market, By Product Type
    • 6.2.1 Human Serum Albumin
    • 6.2.2 Bovine Serum Albumin
    • 6.2.3 Recombinant Albumin
    • 6.2.4 Pharmaceutical Grade Albumin
    • 6.2.5 Research Grade Albumin
  • 6.3 Albumin Sales Market, By Ingredient Type
    • 6.3.1 Fatty Acid-Free Albumin
    • 6.3.2 Low Fatty Acid Albumin
    • 6.3.3 Heat Shock Albumin
    • 6.3.4 Fatty Acid-Enriched Albumin
    • 6.3.5 Others
  • 6.4 Albumin Sales Market, By Distribution Channel
    • 6.4.1 Hospitals and Clinics
    • 6.4.2 Online Pharmacies
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Albumin Sales Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Albumin Sales market is categorized based on

By Product Type

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin
• Pharmaceutical Grade Albumin
• Research Grade Albumin

By Application

• Therapeutics
• Drug Formulation and Drug Delivery
• Vaccines
• Cell Culture
• Diagnostics

By Distribution Channel

• Hospitals and Clinics
• Online Pharmacies
• Retail Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Fatty Acid-Free Albumin
• Low Fatty Acid Albumin
• Heat Shock Albumin
• Fatty Acid-Enriched Albumin
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• CSL Limited
• Grifols S.A.
• Octapharma AG
• Shire Plc (Takeda Pharmaceutical Company)
• Baxter International Inc.
• Albumedix A/S
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Recombumin (biotech company)
• Proliant Biologicals
• Biotest AG
• HUMANZYMES, Inc.
• HemaCare Corporation
• Stemcell Technologies Inc.
• Zeus Scientific Inc.